Fulgent Operating Income from 2010 to 2024

FLGT Stock

USD 20.24 0.11 0.55%

Fulgent Genetics Operating Income yearly trend continues to be comparatively stable with very little volatility. Operating Income is likely to outpace its year average in 2024. Operating Income is earnings before interest and taxes (EBIT), representing the amount of profit Fulgent Genetics generates from its operations. View All Fundamentals

Operating Income

First Reported

2015-03-31

Previous Quarter

-18.9 M

Current Value

-17.1 M

Quarterly Volatility

73.3 M

Yuan Drop

Covid

Check Fulgent Genetics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Fulgent Genetics' main balance sheet or income statement drivers, such as Discontinued Operations of 49.5 K, Depreciation And Amortization of 27.5 M or Interest Expense of 38.9 M, as well as many indicators such as Price To Sales Ratio of 2.83, Dividend Yield of 0.018 or PTB Ratio of 0.72. Fulgent financial statements analysis is a perfect complement when working with Fulgent Genetics Valuation or Volatility modules.

Check out the analysis of Fulgent Genetics Correlation against competitors.

For more information on how to buy Fulgent Stock please use our How to Invest in Fulgent Genetics guide.

Latest Fulgent Genetics' Operating Income Growth Pattern

Below is the plot of the Operating Income of Fulgent Genetics over the last few years. Operating Income is the amount of profit realized from Fulgent Genetics operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Fulgent Genetics is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. It is earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations. Fulgent Genetics' Operating Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Fulgent Genetics' overall financial position and show how it may be relating to other accounts over time.

Operating Income

10 Years Trend

Pretty Stable

Compare to Others All Fundamentals

Operating Income

Timeline

Fulgent Operating Income Regression Statistics

	Arithmetic Mean	27,556,050
	Coefficient Of Variation	343.84
	Mean Deviation	65,380,780
	Median	(990,000)
	Standard Deviation	94,748,617
	Sample Variance	8977.3T
	Range	362.9M
	R-Value	0.22
	Mean Square Error	9211.5T
	R-Squared	0.05
	Significance	0.44
	Slope	4,602,912
	Total Sum of Squares	125682.2T

Fulgent Operating Income History

	2024	-69.1 M
	2023	-72.7 M
	2022	178.5 M
	2021	104.3 M
	2020	290.2 M
	2019	-428 K
	2018	-5.1 M

Other Fundumenentals of Fulgent Genetics

Non Operating Income Net Other

Fulgent Genetics Operating Income component correlations

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Total Liab	Total Current Assets	Property Plant Equipment	Common Stock	Short Term Investments	Capital Surpluse	Long Term Investments	Net Invested Capital	Net Working Capital	Capital Stock	Current Deferred Revenue	Short Term Debt	Short Long Term Debt
Total Assets		1.0	0.99	-0.91	0.98	0.85	0.64	0.88	0.9	0.96	-0.59	0.9	0.98	0.96	0.97	0.9	0.95	0.89	0.79	-0.28
Total Stockholder Equity	1.0		0.99	-0.9	0.99	0.84	0.62	0.87	0.89	0.96	-0.59	0.9	0.98	0.97	0.97	0.89	0.94	0.88	0.78	-0.29
Net Tangible Assets	0.99	0.99		-0.93	0.97	0.82	0.65	0.86	0.87	0.96	-0.6	0.87	0.99	0.98	0.95	0.9	0.95	0.92	0.73	-0.35
Net Debt	-0.91	-0.9	-0.93		-0.85	-0.85	-0.81	-0.88	-0.92	-0.79	0.58	-0.87	-0.9	-0.92	-0.89	-0.97	-0.89	-0.98	-0.76	0.14
Retained Earnings	0.98	0.99	0.97	-0.85		0.77	0.52	0.81	0.86	0.95	-0.48	0.9	0.94	0.96	0.96	0.87	0.9	0.82	0.77	-0.26
Accounts Payable	0.85	0.84	0.82	-0.85	0.77		0.89	0.99	0.93	0.73	-0.6	0.88	0.85	0.73	0.88	0.86	0.89	0.88	0.9	0.02
Net Receivables	0.64	0.62	0.65	-0.81	0.52	0.89		0.87	0.79	0.49	-0.49	0.69	0.68	0.57	0.65	0.77	0.74	0.87	0.73	0.05
Total Liab	0.88	0.87	0.86	-0.88	0.81	0.99	0.87		0.94	0.77	-0.57	0.89	0.88	0.78	0.92	0.88	0.94	0.92	0.88	-0.05
Total Current Assets	0.9	0.89	0.87	-0.92	0.86	0.93	0.79	0.94		0.74	-0.57	0.98	0.85	0.84	0.94	0.97	0.86	0.89	0.95	0.13
Property Plant Equipment	0.96	0.96	0.96	-0.79	0.95	0.73	0.49	0.77	0.74		-0.57	0.75	0.97	0.93	0.89	0.74	0.92	0.8	0.62	-0.51
Common Stock	-0.59	-0.59	-0.6	0.58	-0.48	-0.6	-0.49	-0.57	-0.57	-0.57		-0.51	-0.58	-0.52	-0.54	-0.52	-0.56	-0.55	-0.46	0.16
Short Term Investments	0.9	0.9	0.87	-0.87	0.9	0.88	0.69	0.89	0.98	0.75	-0.51		0.83	0.84	0.94	0.95	0.82	0.82	0.96	0.16
Capital Surpluse	0.98	0.98	0.99	-0.9	0.94	0.85	0.68	0.88	0.85	0.97	-0.58	0.83		0.95	0.93	0.85	0.97	0.92	0.71	-0.41
Long Term Investments	0.96	0.97	0.98	-0.92	0.96	0.73	0.57	0.78	0.84	0.93	-0.52	0.84	0.95		0.92	0.9	0.9	0.89	0.67	-0.35
Net Invested Capital	0.97	0.97	0.95	-0.89	0.96	0.88	0.65	0.92	0.94	0.89	-0.54	0.94	0.93	0.92		0.92	0.94	0.87	0.85	-0.13
Net Working Capital	0.9	0.89	0.9	-0.97	0.87	0.86	0.77	0.88	0.97	0.74	-0.52	0.95	0.85	0.9	0.92		0.85	0.93	0.86	0.04
Capital Stock	0.95	0.94	0.95	-0.89	0.9	0.89	0.74	0.94	0.86	0.92	-0.56	0.82	0.97	0.9	0.94	0.85		0.93	0.73	-0.37
Current Deferred Revenue	0.89	0.88	0.92	-0.98	0.82	0.88	0.87	0.92	0.89	0.8	-0.55	0.82	0.92	0.89	0.87	0.93	0.93		0.73	-0.24
Short Term Debt	0.79	0.78	0.73	-0.76	0.77	0.9	0.73	0.88	0.95	0.62	-0.46	0.96	0.71	0.67	0.85	0.86	0.73	0.73		0.33
Short Long Term Debt	-0.28	-0.29	-0.35	0.14	-0.26	0.02	0.05	-0.05	0.13	-0.51	0.16	0.16	-0.41	-0.35	-0.13	0.04	-0.37	-0.24	0.33

Click cells to compare fundamentals

About Fulgent Genetics Financial Statements

Fulgent Genetics shareholders use historical fundamental indicators, such as Operating Income, to determine how well the company is positioned to perform in the future. Although Fulgent Genetics investors may analyze each financial statement separately, they are all interrelated. The changes in Fulgent Genetics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Fulgent Genetics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.

	Last Reported	Projected for Next Year
Operating Income	-72.7 M	-69.1 M
Non Operating Income Net Other	5.8 M	6.1 M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Fulgent Stock Analysis

When running Fulgent Genetics' price analysis, check to measure Fulgent Genetics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Fulgent Genetics is operating at the current time. Most of Fulgent Genetics' value examination focuses on studying past and present price action to predict the probability of Fulgent Genetics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Fulgent Genetics' price. Additionally, you may evaluate how the addition of Fulgent Genetics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Fulgent Operating Income from 2010 to 2024

Latest Fulgent Genetics' Operating Income Growth Pattern

Fulgent Operating Income Regression Statistics

Fulgent Operating Income History

Other Fundumenentals of Fulgent Genetics

Fulgent Genetics Operating Income component correlations

About Fulgent Genetics Financial Statements

Thematic Opportunities

Explore Investment Opportunities

Additional Tools for Fulgent Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY